Bertrand MAGY, Executive Officer
He is in charge of general management and lead the developments of ATB technology. Bertrand has a PhD in bio-engineering and a master in management from UCL (University of Louvain).
Max Houry, Science & Business Officer
He manages intellectual property of ATB Therapeutics and lead candidate development. Max has a master in molecular biology and a combined master in management and SME creation from UCL.
Ludwig Camusot, Business Officer
Is main focus is business strategy. Ludwig holds an MBA from Solvay Business School. He has a solid biopharma expertise gained across various position such as global market access and life cycle management at Johnson-Johnson , management of bio-oncology division at AstraZeneca BeLux. More recently, he co-founded and was CEO of the Belgium oncology biotech Camel-IDS.
Sébastien Mercx, R&D project leader
He is responsible of operational research and development. Sebastien manages R&D activities. Sebastien has a PhD in molecular biology from UCL.
Nicolas ZEIPPEN, Associate Scientist
He brings his valuable industrial experience in recombinant protein production attained at Unisensor to the R&D group.
Nicolas has got a master in molecular biology from University of Namur.
Anaïs JADOT, Administrative assistant
Anaïs is supporting part-time the financial and accounting management of the company. Anaïs is also Direction assistant at the Fiduciaire de Wallonie.